Is There a Link Between Mounjaro and Blindness?

Where did the concern about blindness come from?

The story began with an observational study published in 2024, which examined records from a US ophthalmology database and found that people prescribed semaglutide (the active ingredient in Wegovy) appeared to have higher rates of NAION diagnosis than comparable patients on other medicines. NAION, or non-arteritic anterior ischaemic optic neuropathy, is a condition where the blood supply to the optic nerve is suddenly disrupted, causing rapid, painless vision loss, typically in one eye.

That study attracted attention because the association was statistically notable. It did not, however, prove that the medicine caused NAION. Observational data cannot rule out confounding factors: people taking weight-loss medicines often have underlying conditions (including type 2 diabetes, high blood pressure and cardiovascular disease) all of which independently raise the risk of NAION. Separating the medicine's effect from the disease background is genuinely difficult.

Tirzepatide (Mounjaro) was not the primary focus of that paper, and the researchers acknowledged the data for it were too sparse to draw conclusions. For a thorough overview of how tirzepatide works and what it is licensed for, the tirzepatide information page covers the mechanism and the trial programme in detail.

Has the MHRA or any regulator confirmed a causal link?

As of mid-2026, no UK or European regulator has confirmed a causal relationship between tirzepatide and blindness or NAION. The MHRA monitors all medicines under its pharmacovigilance framework, and Mounjaro carries a Black Triangle (▼) designation, which means it is subject to additional post-authorisation safety monitoring precisely because it is relatively new. Prescribers and patients are encouraged to report any suspected side effect, including eye symptoms, through the Yellow Card scheme.

The MHRA's published guidance on GLP-1 medicines for weight loss does not list vision loss as a confirmed adverse effect of tirzepatide. The current known side-effect profile is dominated by gastrointestinal symptoms (nausea, loose stools, indigestion) particularly in the weeks after starting treatment or after a dose increase. Ocular symptoms are not among the commonly reported effects in the SURMOUNT clinical programme, which involved thousands of participants across SURMOUNT-1 and the broader trial series.

That said, the absence of regulatory confirmation is not the same as the absence of risk. This is an active area of scientific discussion, and anyone who wants to understand what the evidence actually says about Mounjaro and blindness should raise it during their clinical consultation, before treatment starts, not after.

What should patients watch for, and when is it urgent?

NAION typically presents without warning: a sudden, painless drop in vision in one eye, sometimes noticed on waking. It can look like a shadow or blurred patch that does not clear. This is a medical emergency regardless of whether a person is on any medicine, the optic nerve has very limited capacity to recover once injured, so early assessment matters.

If you are taking Mounjaro and experience any sudden change in vision (blurring, loss of field, double vision, or unusual floaters) call 111 or attend an eye casualty unit the same day. Do not simply pause your pen and wait. The Patient Information Leaflet stored with your pen in the fridge provides a full list of symptoms that require immediate attention; reading it once when you start treatment is worthwhile.

For broader context on the side-effect picture and what monitoring is recommended during treatment, the Mounjaro overview page covers the full profile. The NHS tirzepatide medicine page also lists urgent symptoms to watch for, written in plain language.

Does this change who Mounjaro is suitable for?

Not in any formal licensed sense, as things stand. Current prescribing guidance for tirzepatide does not exclude patients on the basis of optic nerve history, and regulators have not added a specific NAION warning to the UK Summary of Product Characteristics. That said, prescribers take individual risk factors seriously, and patients who have searched for answers to questions such as whether Mounjaro can make you blind will find a detailed clinical breakdown of that question worth reading before their consultation. A clinical consultation is the right moment to disclose any eye conditions, history of sudden vision changes, or high-risk diagnoses like untreated high blood pressure or diabetes-related eye disease.

Eli Lilly's UK list price for Mounjaro changed significantly in September 2025; for context on how that affects private prescription costs, the Mounjaro price increase explainer sets out what changed and why. Cost questions aside, the more important factor is making sure any treatment decision is made with a full clinical picture, including an understanding of what it means for Mounjaro to be described as a blind injection and how that term is sometimes misread as a safety concern. At nume, a named GPhC-registered prescriber (not a decision algorithm) personally reads your consultation before anything is approved or dispatched. Questions about eye history, current medications and existing conditions are part of that review. If you would like that assessment, the clinical team page explains who oversees prescribing, and you can start your free consultation when you are ready.